Freeflow Ventures is a venture capital firm established in 2019 and based in Pasadena, California. The firm specializes in pre-seed and seed-stage investments in companies addressing complex challenges in human and planetary health. Freeflow has a strong connection to the California Institute of Technology and the Jet Propulsion Laboratory, which informs its investment strategy. The firm's focus areas include medical devices, energy production and storage, technology, autonomous systems, food and agriculture, and new materials. With general partners David Fleck and Kevin Barrett at the helm, Freeflow combines over 50 years of experience in technology and healthcare. The firm also benefits from an advisory board that includes notable figures from prominent venture firms, and it collaborates with a diverse array of syndicate partners to enhance its investment capabilities.
Mitico specializes in advanced carbon capture solutions, utilizing a patented granulated metal carbonate sorption technology developed at Caltech. This innovative approach effectively captures over 95% of carbon dioxide emissions from post-combustion sources, such as gas-fired power plants, boilers, and waste-to-energy facilities. By providing carbon capture, utilization, and storage (CCUS) as a service, Mitico enables clients to significantly reduce their carbon emissions at a lower cost compared to conventional methods. The company's technology aims to facilitate mass mitigation of carbon emissions, making it an essential partner for industries seeking to address environmental challenges and transition towards more sustainable practices.
MIIST Therapeutics
Seed Round in 2025
MIIST Therapeutics focuses on advancing pulmonary drug delivery systems and digital platforms to improve inhaled drug therapies. The company is developing innovative technology aimed at facilitating smoking cessation and addressing the health risks associated with tobacco use. By creating inhaler technology that targets the deepest areas of the lungs, MIIST enables rapid absorption of medications. This approach aims to enhance the effectiveness of inhaled treatments for various health conditions, starting with smoking addiction, and ultimately seeks to reduce the significant health burdens related to tobacco consumption.
Aralez Bio
Series A in 2024
Aralez Bio specializes in the sustainable production of noncanonical amino acids (ncAAs), which are also known as unusual or unnatural amino acids. The company has developed a novel enzymatic method that allows for the synthesis of over 100 ncAAs with perfect enantiopurity in a single step, using water as the sole byproduct. This innovative approach provides clients with access to essential amino acids required for advancements in pharmaceuticals, agriculture, and functional materials, thereby supporting various sectors in their product development efforts.
Persperity Health
Pre Seed Round in 2024
Persperity Health is a technology company specializing in women's health. It develops a non-invasive, real-time hormone tracking platform, combining biosensors and AI-driven data analytics. This platform empowers women with personalized insights into their hormonal health, transforming the management of fertility, menopause, and overall wellness, and enabling them to take control of their hormonal well-being.
Esperto Medical
Series A in 2024
Esperto Medical is a medical device company based in Irvine, California, focused on developing advanced wearable diagnostic tools for both hospital and remote patient monitoring. The company utilizes a proprietary technology called resonance sonomanometry, which employs acoustic stimulation to measure blood pressure continuously and noninvasively, eliminating the need for calibration. By offering round-the-clock monitoring capabilities, Esperto Medical aims to enhance patient care and accessibility, allowing individuals to track their vital signs conveniently from home or within clinical settings.
Calicat
Series A in 2024
Calicat is a clean-energy company developing a proprietary electrocatalyst discovery process for electrolyser. The company electrocatalyst discovery is an unprecedented, proprietary, end-to-end ultrahigh throughput AI and data-driven process focused on the discovery of new catalysts for the generation of clean hydrogen and fuel cell power production. The process prepares, characterizes, and quantifies the catalytic activity of millions of compositions per month and then closes the loop with big data analysis and AI to refine/guide the search.
Curry it
Seed Round in 2024
Curry it is a food manufacturing company that offers ready-to-cook curries, pastes, and mixes for vegetarian and non-vegetarian recipes.
Holoclara
Series A in 2024
Holoclara is an immunotherapy company focused on developing treatments for autoimmune disorders using nematode-derived molecules. The company aims to provide relief to individuals suffering from these conditions by offering a range of services that include the delivery of therapeutics derived from worm species. These molecules are identified for their potent therapeutic properties and are being developed into safe, orally available treatments. Holoclara’s initiatives are designed to enable patients to lead healthier lives while addressing the challenges posed by autoimmune disorders.
StrokeDx
Seed Round in 2024
StrokeDx specializes in creating innovative and portable diagnostic devices aimed at improving stroke care. The company leverages advanced machine learning and artificial intelligence to enhance the diagnostic accuracy and imaging capabilities of its microsensors. These devices are designed to detect blood in the brain and generate predictive images of stroke locations, allowing for rapid triage and diagnosis. By offering a cost-effective alternative to traditional methods, StrokeDx aims to reduce the time to treatment, ultimately improving patient outcomes in emergency situations.
Catena Biosciences
Seed Round in 2024
Catena Biosciences is a biotechnology company focused on advancing protein conjugation technology to develop novel therapeutics for autoimmune disorders, oncology, and vaccine development. The company specializes in the efficient and selective attachment of proteins using natural amino acids, specifically tyrosine and cysteine. This innovative approach allows researchers to create biologic structures more rapidly than traditional methods, enhancing the potential for medical research and treatment options in various disease areas. Catena Biosciences aims to contribute significantly to the field of biomedicine through its cutting-edge technology and applications.
Tierra Biosciences
Series A in 2024
Tierra Biosciences is a synthetic biology company focused on advancing the discovery of bioengineered products through innovative technologies. Founded in 2015 and headquartered in San Francisco, California, the company specializes in cell-free technologies that facilitate the production of complex molecules that traditional laboratory cells find challenging to generate. Its Next Generation Expression platform integrates automation, computation, and high-throughput cell-free expression to enable rapid, experimentally validated data collection, surpassing the limitations of simulation-based methods. By combining cell-free protein production with artificial intelligence, Tierra Biosciences aims to streamline protein manufacturing, making it as accessible as e-commerce. The company was formerly known as Synvitrobio, Inc., before rebranding in September 2018.
Captura
Series A in 2024
Captura is a company focused on direct ocean carbon capture, developing technology to efficiently extract carbon dioxide from ocean water. Its innovative system leverages the natural carbon removal capabilities of the ocean to capture atmospheric CO2 on a large scale and at a low cost. This approach not only addresses the urgent need for carbon sequestration but also aligns with the increasing demand for carbon credits in the market. By utilizing renewable electricity and ocean water, Captura's technology operates sustainably, producing no harmful by-products and contributing significantly to efforts against climate change.
Mitico
Seed Round in 2023
Mitico specializes in advanced carbon capture solutions, utilizing a patented granulated metal carbonate sorption technology developed at Caltech. This innovative approach effectively captures over 95% of carbon dioxide emissions from post-combustion sources, such as gas-fired power plants, boilers, and waste-to-energy facilities. By providing carbon capture, utilization, and storage (CCUS) as a service, Mitico enables clients to significantly reduce their carbon emissions at a lower cost compared to conventional methods. The company's technology aims to facilitate mass mitigation of carbon emissions, making it an essential partner for industries seeking to address environmental challenges and transition towards more sustainable practices.
Continuum Space Systems
Seed Round in 2023
Continuum Space Systems develops a Unified Mission Management platform aimed at enhancing the planning and execution of space missions. This software as a service (SaaS) tool allows companies to efficiently manage all stages of a mission, from ideation through design to operational execution. By providing advanced technological solutions, the platform enables organizations to conduct space missions that are safer, less risky, and more cost-effective.
Hydrosat
Series A in 2023
Hydrosat is a climate technology company established in 2017 and headquartered in Washington, D.C. The company specializes in utilizing thermal imagery from satellites to assess water stress in agriculture, thereby enhancing food security, public safety, and environmental management. Hydrosat provides geospatial analytics services that enable organizations to monitor and manage data related to plant health. By transforming thermal infrared satellite imagery into actionable insights, Hydrosat supports various sectors, including agriculture, financial services, and government, in making informed decisions regarding water resource management.
Switch Therapeutics
Series A in 2023
Switch Therapeutics is a biotechnology company established in 2020 and located in San Francisco, California. The company focuses on developing innovative RNA interference (RNAi) therapies aimed at transforming the treatment of various diseases, particularly those affecting the central nervous system and other systemic conditions with significant unmet medical needs. By integrating nucleic acid nanotechnology with RNAi science, Switch Therapeutics creates biomarker-gated genetic medicines designed to activate RNA molecules and therapies specifically in targeted cells. This targeted approach aims to enhance the effectiveness of treatments for central nervous system diseases, providing healthcare providers with advanced therapeutic options.
Wild Microbes
Pre Seed Round in 2023
Wild Microbes is a microbial platform focused on producing sustainable chemicals, ingredients, and materials through the application of synthetic biology. By developing new microbial strains, the company enhances the efficiency and cost-effectiveness of producing a wide range of products, including plastics and proteins. Their expertise in cultivating and engineering microbes allows various industries to adopt more sustainable practices, promoting environmental responsibility while meeting market demands. Wild Microbes aims to accelerate the transition to sustainable alternatives by leveraging innovative microbial technologies.
Membrion
Series B in 2023
Membrion, Inc., founded in 2016 and based in Seattle, Washington, specializes in the manufacturing and commercialization of advanced membranes that filter molecules, including ions, under a variety of conditions such as heat, acidity, and biological sensitivity. Originating as a spin-out from the University of Washington, Membrion has received funding from multiple organizations, including the National Science Foundation and private investors, which has facilitated the transition from research to commercial production. The company's innovative ion exchange membrane technology is designed for applications in flow batteries, water purification, fuel cells, and pharmaceuticals, offering clients membranes that feature a longer lifespan and reduced costs.
Captura
Series A in 2023
Captura is a company focused on direct ocean carbon capture, developing technology to efficiently extract carbon dioxide from ocean water. Its innovative system leverages the natural carbon removal capabilities of the ocean to capture atmospheric CO2 on a large scale and at a low cost. This approach not only addresses the urgent need for carbon sequestration but also aligns with the increasing demand for carbon credits in the market. By utilizing renewable electricity and ocean water, Captura's technology operates sustainably, producing no harmful by-products and contributing significantly to efforts against climate change.
Calicat
Series A in 2022
Calicat is a clean-energy company developing a proprietary electrocatalyst discovery process for electrolyser. The company electrocatalyst discovery is an unprecedented, proprietary, end-to-end ultrahigh throughput AI and data-driven process focused on the discovery of new catalysts for the generation of clean hydrogen and fuel cell power production. The process prepares, characterizes, and quantifies the catalytic activity of millions of compositions per month and then closes the loop with big data analysis and AI to refine/guide the search.
Homo Deus Tech Solutions
Seed Round in 2021
Comprehensive health care solutions to bring, nurse, assistant, meds, basic diagnostics to the home along with paneled doctors for virtual consultations and home visits.
Hydrosat
Seed Round in 2021
Hydrosat is a climate technology company established in 2017 and headquartered in Washington, D.C. The company specializes in utilizing thermal imagery from satellites to assess water stress in agriculture, thereby enhancing food security, public safety, and environmental management. Hydrosat provides geospatial analytics services that enable organizations to monitor and manage data related to plant health. By transforming thermal infrared satellite imagery into actionable insights, Hydrosat supports various sectors, including agriculture, financial services, and government, in making informed decisions regarding water resource management.
Hydrosat
Seed Round in 2021
Hydrosat is a climate technology company established in 2017 and headquartered in Washington, D.C. The company specializes in utilizing thermal imagery from satellites to assess water stress in agriculture, thereby enhancing food security, public safety, and environmental management. Hydrosat provides geospatial analytics services that enable organizations to monitor and manage data related to plant health. By transforming thermal infrared satellite imagery into actionable insights, Hydrosat supports various sectors, including agriculture, financial services, and government, in making informed decisions regarding water resource management.
Appia Bio
Series A in 2021
Appia Bio is a biotechnology company dedicated to the research and development of allogeneic cell therapies that can be readily available for patients. The company focuses on creating engineered cell therapies for various medical conditions using its innovative ACUA technology platform. This platform utilizes the biology of lymphocyte development along with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to produce CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes derived from hematopoietic stem cells. By maturing and scaling healthy stem cells into these therapies, Appia Bio aims to provide safe and targeted cancer treatments, thereby enhancing accessibility to off-the-shelf cell therapies for physicians and patients alike.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.